SCHEMBL2538468

SCHEMBL2538468

O=C(O)CN(CC(=O)O)C[C@H](Cc1ccc(NC(=O)CBr)cc1)N(CC(=O)O)CC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
ATM Q13315 1/20 0.43
CA1 P00915 10/20 0.41
CA2 P00918 10/20 0.41
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
CA4 P22748 3/20 0.39
POLB P06746 1/20 0.38
CHRM1 P11229 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
HIF1A Q16665 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7170464 1.00 KMT2A (0.43) KMT2AATMCA1CA2CA12
SCHEMBL443090 0.91 KMT2A (0.41) KMT2AATMCA1CA2CA12
SCHEMBL437799 0.91 KMT2A (0.41) KMT2AATMCA1CA2CA12
SCHEMBL6560864 0.89 KMT2A (0.37) KMT2AATMCA1CA2CA12
SCHEMBL437797 0.86 KMT2A (0.38) KMT2AATMCA1CA2CA12
SCHEMBL437798 0.86 KMT2A (0.38) KMT2AATMCA1CA2CA12
SCHEMBL443089 0.86 KMT2A (0.38) KMT2AATMCA1CA2CA12
SCHEMBL23831089 0.85 CA1 (0.41) KMT2AATMCA1CA2CA12
SCHEMBL29361887 0.85 CA1 (0.41) KMT2AATMCA1CA2CA12
SCHEMBL13814038 0.84 KMT2A (0.44) KMT2AATMCA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12111313-B2 Chelator-coated field effect transistor and devices and methods using same Autonomous Medical Devices Inc. (US) 2024-10-08 US claimed
CN-116296702-B Dead-living dye capable of customizing detection channel based on mass spectrometry detection technology and preparation method and application thereof 杭州普罗亭医学检验实验室有限公司 2023-12-29 CN claimed
CN-116296702-A Dead-living dye capable of customizing detection channel based on mass spectrometry detection technology and preparation method and application thereof 杭州普罗亭医学检验实验室有限公司 2023-06-23 CN claimed
US-20210293798-A1 Chelator-Coated Field Effect Transistor and Devices and Methods Using Same Autonomous Medical Devices Inc. (US) 2021-09-23 US claimed
EP-3837541-A1 CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME Autonomous Medical Devices Incorporated (US) 2021-06-23 EP claimed
WO-2020037078-A1 CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME Sensor-Kinesis Corporation (US) 2020-02-20 WO claimed
US-12111313-B2 Chelator-coated field effect transistor and devices and methods using same Autonomous Medical Devices Inc. (US) 2024-10-08 US disclosed
CN-116296702-B Dead-living dye capable of customizing detection channel based on mass spectrometry detection technology and preparation method and application thereof 杭州普罗亭医学检验实验室有限公司 2023-12-29 CN disclosed
CN-116296702-A Dead-living dye capable of customizing detection channel based on mass spectrometry detection technology and preparation method and application thereof 杭州普罗亭医学检验实验室有限公司 2023-06-23 CN disclosed
US-20210293798-A1 Chelator-Coated Field Effect Transistor and Devices and Methods Using Same Autonomous Medical Devices Inc. (US) 2021-09-23 US disclosed
EP-3837541-A1 CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME Autonomous Medical Devices Incorporated (US) 2021-06-23 EP disclosed
WO-2020037078-A1 CHELATOR-COATED FIELD EFFECT TRANSISTOR AND DEVICES AND METHODS USING SAME Sensor-Kinesis Corporation (US) 2020-02-20 WO disclosed
EP-2561334-A1 PRODUCTS AND METHODS FOR TISSUE PRESERVATION Genvault Corporation (US) 2013-02-27 EP disclosed
WO-2011130280-A1 PRODUCTS AND METHODS FOR TISSUE PRESERVATION GENVAULT CORPORATION (US) 2011-10-20 WO disclosed
US-20110256530-A1 PRODUCTS AND METHODS FOR TISSUE PRESERVATION GENVAULT CORPORATION (US) 2011-10-20 US disclosed
US-20040167330-A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnois and therapeutic agents THERAPHARM GMBH (CH) 2004-08-26 US disclosed
EP-1406879-A1 NOVEL CHELATING AGENTS AND CONJUGATES THEREOF, THEIR SYNTHESIS AND USE AS DIAGNOSTIC AND THERAPEUTIC AGENTS Therpharm GmbH (CH) 2004-04-14 EP disclosed
WO-2003008394-A1 NOVEL CHELATING AGENTS AND CONJUGATES THEREOF, THEIR SYNTHESIS AND USE AS DIAGNOSTIC AND THERAPEUTIC AGENTS THERAPHARM GMBH (CH) 2003-01-30 WO disclosed
US-4917878-A RADIOSCINTIGRAPHIC DETECTION; CHELATE COMPOUNDS THOMAS JEFFERSON UNIVERSITY (US) 1990-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167330-A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnois and therapeutic agents PAICS, BPGM, PCNA KMT2A 1331/4885ATM 3276/4885CA1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.